+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the use of bedaquiline compared to standard treatments to prevent tuberculosis disease in people living with HIV and close contacts of adults with drug-susceptible or rifampin-resistant tuberculosis. This Phase IIIII open-label trial aims to show that 4 weeks of bedaquiline is not less effective than current WHO-recommended regimens for preventing tuberculosis in these high-risk groups. Participants are assigned to one of three treatment groups 4 weeks of daily bedaquiline, 3 months of weekly isoniazid and rifapentine, or 6 months of daily levofloxacin. The study includes groups at high risk, such as children, adolescents, adults, pregnant people, and people living with HIV, with treatments adjusted by weight or age. Treatment durations vary by regimen, and those with rifampin-resistant tuberculosis receive levofloxacin. During the study, participants undergo safety and treatment completion assessments up to 18 or 36 weeks depending on the group. Researchers monitor for adverse events, treatment adherence, and incidence of tuberculosis disease for up to 72 weeks after treatment starts. Laboratory tests, chest x-rays, and pregnancy tests are conducted before enrollment, and safety is closely followed throughout the study period lasting over one year from treatment initiation.

All AgesAll GendersPhase 2Phase 3
8 locations
I

Actively Recruiting

This research aims to improve HIV healthcare for mothers living with HIV and their newborns in Tanzania and Mozambique, focusing on preventing HIV transmission from mother to child. The study evaluates whether adding maternal HIV viral load testing at delivery better identifies mother-child pairs at high risk of transmission and whether high-risk infants receive appropriate prevention and care. It builds on previous findings about early infant HIV treatment challenges and seeks to reduce access inequities in rural areas by expanding HIV testing services through a hub-and-spoke referral system. The study involves maternal HIV viral load testing at delivery to assess vertical HIV transmission risk, combined with WHO clinical criteria for risk classification. The intervention includes personnel support for managing high-risk cases, eHealth tools for sharing test results between health facilities, and enhanced counseling for high-risk mother-baby pairs. High-risk infants and their mothers are followed long-term for up to 12 months to monitor health outcomes and treatment adherence. Participants will undergo HIV testing at birth and follow-up visits at 4-6 weeks, 14 weeks, 6 months, and 12 months, with assessments of viral suppression, drug resistance, and clinical outcomes. The study also collects socio-behavioral data through interviews and questionnaires to understand factors affecting treatment outcomes. Researchers will measure key program indicators such as the proportion of high-risk newborns tested and started on treatment within seven days, turnaround times for testing, and cost-effectiveness of the intervention package. Continuous support and counseling are provided throughout the study duration.

Age: 18Years +FEMALE
2 locations
P

Actively Recruiting

Researchers are investigating new treatment options for adults with newly diagnosed, drug-sensitive pulmonary tuberculosis through a phase 2BC open-label platform study. The trial compares several experimental drug regimens with a standard control treatment to assess efficacy and safety. Participants include adults aged 18 to 65 years with confirmed pulmonary tuberculosis sensitive to rifampicin and isoniazid. The study aims to optimize doses of existing drugs and introduce new medications to improve treatment outcomes. The study is divided into three stages. In stage 1, participants are randomly assigned to the control or one of two experimental arms containing high-dose rifampicin and other drugs for 12 to 17 weeks. Stage 2 adds an experimental arm including the drug BTZ-043, with participants allocated across four arms in varying ratios. Stage 3 begins after stages 1 and 2 complete enrollment, comparing the control arm with two new experimental arms involving novel drug combinations. Treatments are given once daily, with dosages adjusted by arm and weight. Participants will undergo sputum testing, chest X-rays, and molecular tests to confirm tuberculosis and drug sensitivity before enrollment. During the study, researchers will monitor participants through regular clinical assessments, laboratory tests, and electrocardiograms to track treatment response and safety. The main outcomes measured include time to stable culture conversion and changes in mycobacterial load. Safety is evaluated by recording adverse events and laboratory abnormalities over the treatment period, with follow-up continuing up to 12 months after randomization.

Age: 18Years - 65YearsAll GendersPhase 2
10 locations
E

Actively Recruiting

Researchers are evaluating new treatment regimens for pulmonary tuberculosis TB that aim to be faster while maintaining safety and effectiveness. This trial is conducted by the UNITE4TB consortium, a collaboration of universities and pharmaceutical companies, funded by the European Union. The study focuses on adults with newly diagnosed rifampicin-susceptible pulmonary TB and includes both drug-susceptible and potentially drug-resistant cases to find improved therapies. The trial has two main parts. In Phase 2B, up to 700 participants will be randomly assigned to one of several treatment groups, including a standard 24-week regimen and up to 16-week novel regimens combining new drugs like BTZ-043 and GSK3036656 with existing TB medications. Phase 2C will involve up to 1800 participants receiving selected regimens from Phase 2B for varying durations between 8 and 16 weeks. The study drugs are given orally with specific doses, and treatment combinations may change during the trial. Participants will be followed for a total of 72 weeks to monitor treatment response and safety. Assessments include measuring the time to positivity of sputum cultures, adverse events, and treatment outcomes such as relapse or failure. Safety monitoring covers serious and special interest adverse events. The trial includes regular visits and laboratory tests to evaluate the effectiveness and tolerability of the treatments over the duration of the study.

Age: 18Years +All GendersPhase 2
11 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two sorfequiline-based treatment regimens combined with pretomanid and linezolid for adults aged 18 to 65 with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis. This phase 2, randomized, multi-center, partially blinded trial involves about 100 participants in South Africa and Tanzania and aims to assess treatment safety and bacterial culture conversion times. Participants are randomly assigned to one of two oral treatment groups one receives a loading dose regimen of sorfequiline 200 mg daily for 4 weeks followed by 100 mg daily for 13 weeks, and the other receives sorfequiline 100 mg daily for 17 weeks. Both groups also take pretomanid 200 mg and linezolid 600 mg daily, with the treatment administered once daily with food. The trial includes a screening period up to 11 days before treatment, a 17-week treatment period, and a 52-week follow-up after treatment ends. During the study, participants will undergo safety monitoring including assessments of adverse events, ECGs, vital signs, lab tests, vision checks, and peripheral neuropathy evaluations. Researchers will also measure treatment efficacy by monitoring time to stable sputum culture conversion and treatment outcomes at 26 and 52 weeks post-treatment. Pharmacokinetics and quality of life are additionally assessed throughout the study duration.

Age: 18Years - 65YearsAll GendersPhase 2
12 locations
E

Actively Recruiting

Anaemia occurs when the body lacks enough healthy red blood cells to carry oxygen, causing symptoms like tiredness, weakness, dizziness, and shortness of breath. It is common among women due to monthly blood loss during periods, and can lead to complications during pregnancy such as early birth or heavy bleeding. This trial investigates whether adding tranexamic acid TXA, a medicine used to treat heavy periods, to usual iron and vitamin supplements improves anaemia treatment in menstruating women compared to supplements alone. Participants are assigned to one of two groups one group takes TXA tablets three times daily during their menstrual period for up to six consecutive cycles maximum 9 months, along with standard oral iron and folic acid supplements for three months. The other group receives placebo tablets on the same schedule plus the standard iron and folic acid supplements. The study is randomized, placebo-controlled, and quadruple-blinded to evaluate the effects of TXA combined with supplements versus supplements alone. During the trial, participants attend in-person follow-up visits where researchers measure anaemia status, hemoglobin levels, menstrual blood loss, iron levels, inflammation markers, menstrual pain, and quality of life related to menstrual bleeding. These assessments occur from enrollment through the final visit after six menstrual periods or up to nine months. The primary outcome is the proportion of participants with anaemia by the end of the treatment period. Participants are monitored for safety and wellbeing throughout the study.

Age: 18Years +FEMALEPhase 3
3 locations
S

Actively Recruiting

Researchers are studying whether tranexamic acid TXA given just before childbirth can prevent postpartum haemorrhage PPH, a leading cause of maternal deaths worldwide. This Phase 3 trial focuses on women at higher risk of PPH, comparing different methods of administering TXA to assess its effects on preventing heavy bleeding and evaluating potential side effects and important maternal health outcomes. Participants will be randomly assigned to one of three groups receiving TXA as intramuscular injections plus a placebo intravenous injection, TXA by intravenous injection plus placebo intramuscular injections, or placebo by both routes. The study compares the effects of intramuscular and intravenous TXA administered around the time of delivery to determine which method may best prevent PPH. During the trial, participants will be closely monitored for blood loss up to 24 hours after birth, vital signs, and any bleeding-related complications or side effects. Researchers will also assess blood tests, surgical outcomes for cesarean births, maternal adverse events, and neonatal health up to 42 days postpartum. The study aims to provide detailed safety and effectiveness data while participants receive standard hospital care, with total participation lasting through hospital discharge or up to 42 days after birth.

Age: 18Years +FEMALEPhase 3
1 location